

Mouse LBP Alexa Fluor® 700-conjugated Antibody

Antigen Affinity-purified Polyclonal Sheep IgG Catalog Number: AF6635N

100 µg

DESCRIPTION	
Species Reactivity	Mouse
Specificity	Detects mouse LBP in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant human LBP is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse LBP Gly25-Val481 (Ser102Arg, Tyr284His) Accession # NP_032515
Conjugate	Alexa Fluor 700 Excitation Wavelength: 675-700 nm Emission Wavelength: 723 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

LBP (Lipopolysaccharide binding protein) is a 58-62 kDa, single-chain glycoprotein member of the BPI/LBP family, BPI/PLUNC/PSP superfamily of lipid-binding proteins (1-3). It is secreted by a number of mammalian cell types, including hepatocytes (4), gingival keratinocytes (5), intestinal Paneth cells (6), and type II Greater alveolar cells (7). LBP is considered to be a class 1 APR (acute phase reactant) that is induced upon exposure to both IL-1 and IL-6 (8). These two cytokines appear upon immune cell exposure to pathogenic microbes. Following its synthesis and release, LBP is known to interact with bacterial wall components,

lipopolysaccharide/LPS/Lipid A from Gram (Gm) bacteria, and lipoteichoic acid/LTA from Gm⁺ bacteria (9-13). In the case of LPS, this interaction appears to occur both in the bacterial cell wall, and within the intercellular space, where LPS micelles naturally form following bacterial death and cell wall dissolution (14-17). LBP is posited to induce disassembly of LPS micelles, allowing for LPS binding to LBP, and a heparin-mediated transfer of LPS from LBP to membrane-bound CD14 on the surface of monocytes/macrophages (15, 18). This CD14:LPS complex activates a TLR4:MD2 membrane complex, resulting in the production of NO and TNF-α (19). TNF-α serves as a chemoattractant for PMNs, and an initiator of coagulation that helps to wall-off and localize microbial elements (16). Notably, increased concentrations of LBP are also associated with parasitic infections (Trypanosoma), and may contribute to the immune response towards parasites (20). In addition to the above, LBP is also reported to transfer LPS to lipoproteins, particularly HDL and LDL (19, 21-23). For LDL, this transfer appears to be inhibitory to monocyte activation; for HDL, the effect may be either stimulatory or inhibitory, depending upon the circumstances (19). Mouse LBP is synthesized as a 481 amino acids (aa) precursor that contains a 25 aa signal sequence and a 456 aa mature region (aa 26-481) (24). It contains an N-terminal LPS binding region plus a likely C-terminal LPS transfer region (24, 25). Mature mouse LBP shares 68% and 88% aa identity with human and rat LBP, respectively (11, 25).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Rev. 9/16/2025 Page 1 of 1

Global | bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL: 1.612.379.2956

Bio-Techne®

USA | TEL: 800.343.7475 Canada | TEL: 855.668.8722 Europe | Middle East | Africa TEL: +44.0.1235.529449 China | info.cn@bio-techne.com TEL: 400.821.3475